NCT02398513View on ClinicalTrials.gov

Regorafenib Phase I Study in Mainland Chinese Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

June 30, 2016

Conditions
Oncology
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

Regorafenib 160 mg per oral

Trial Locations (1)

200032

Shanghai

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02398513 - Regorafenib Phase I Study in Mainland Chinese Patients | Biotech Hunter | Biotech Hunter